Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
NKTR > SEC Filings for NKTR > Form 8-K on 14-Jan-2014All Recent SEC Filings

Show all filings for NEKTAR THERAPEUTICS | Request a Trial to NEW EDGAR Online Pro

Form 8-K for NEKTAR THERAPEUTICS


14-Jan-2014

Other Events, Financial Statements and Exhibits


Item 8.01 Other Events.

On January 14, 2014, Nektar Therapeutics, a Delaware Corporation ("Nektar"), issued a press release announcing that the first subjects were dosed in a Phase 1 clinical study for NKTR-171. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On January 14, 2014, Nektar also issued a press release announcing that etirinotecan pegol (NKTR-102) passes interim efficacy analysis for the BEACON pivotal Phase 3 clinical study in patients with metastatic breast cancer. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

99.1 Press Release titled "First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain" issued by Nektar Therapeutics on January 14, 2014.
99.2 Press Release titled "Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer" issued by Nektar Therapeutics on January 14, 2014.

  Add NKTR to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for NKTR - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.